An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Athersys to Participate in the Bank of America Securities 2022 Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Athersys, Inc. (Nasdaq: ATHX) will participate in a fireside chat at the Bank of America Securities 2022 Global Healthcare Conference on May 11, 2022, at 4:00 p.m. PT in Las Vegas. CEO Dan Camardo and CFO Ivor Macleod will represent the company. Investors can schedule one-on-one meetings with the management during the conference. A live webcast will be available on the company’s website, with an archived replay accessible afterward. Athersys focuses on developing therapeutic products, notably the MultiStem® cell therapy for various medical conditions.
Positive
None.
Negative
None.
CLEVELAND--(BUSINESS WIRE)--
Athersys, Inc. (Nasdaq: ATHX), announced today that Dan Camardo, Chief Executive Officer, and Ivor Macleod, Chief Financial Officer, will participate in a fireside chat at the Bank of America Securities 2022 Global Healthcare Conference on Wednesday, May 11, 2022 at 4:00 p.m. PT in Las Vegas. The Company’s management team will also participate in one-on-one meetings with institutional investors during the conference.
Investors interested in arranging a meeting with the Company’s management during the conference should contact the Bank of America conference coordinator. A live webcast of the event can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website. An archived replay of the webcast will be available on the Company's website after the conference for a limited time.
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
